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Abstract
Background: Fatigue in COPD impairs functional status; however there are few studies examining
mechanistic pathways of this symptom. The aims of this study are to compare fatigue between
COPD patients and healthy age-matched subjects, and to identify predictors of fatigue in COPD.
Methods: Seventy four COPD patients, mean age 69.9 (49-87) yrs, mean (SD) % predicted FEV1
46.5 (20.0) % and FEV1/FVC ratio 0.45 (0.13) and 35 healthy subjects, mean age 67.1 (50-84) yrs
completed the Multidimensional Fatigue Inventory (MFI 20). Patients' assessment included
Depression (HADS), lung function, BMI, muscle strength, incremental shuttle walk test (ISWT),
exercise oxygen saturation (SpO2), Borg breathlessness (CR-10) and exertion (RPE). Serum level
of Interleukin 6 (IL-6) was recorded. Differences in MFI 20 between groups were examined and
predictors of fatigue identified using logistic regression.
Results: Significant differences (p < 0.01) were found between the COPD and healthy subjects for
all MFI 20 dimensions. There were significant differences when classified according to GOLD and
dyspnoea stages for selected dimensions only. Predictors of General Fatigue were depression,
muscle strength and end SpO2 (R2 = .62); of Physical Fatigue: depression, % predicted FEV1, ISWT
and age (R2 = .57); Reduced Activity: % predicted FEV1, BMI and depression (R2 = .36); Reduced
Motivation: RPE, depression and end SpO2 (R2 = .37) and Mental Fatigue: depression and end SpO2
(R2 = .38).
Conclusion: All dimensions of fatigue were higher in COPD than healthy aged subjects. Predictive
factors differ according to the dimension of fatigue under investigation. COPD-RF is a multi
component symptom requiring further consideration.
Background
Fatigue, as a symptom in chronic obstructive pulmonary
disease (COPD) may have diverse manifestations, such as
physical or mental tiredness, loss of attention, concentra-
tion or motivation [1,2]. It is an important [3-5] and
highly prevalent symptom [6,7] with data from one study
suggesting that 90% of COPD patients may report fatigue
[6]. Although fatigue in COPD is acknowledged by clini-
cians, it is often neglected. In fact, compared with cancer
the predictors and patho-mechanisms of fatigue are
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standing regarding the management of fatigue. There are
evident associations between fatigue, impaired quality of
life and increased depression [8-10]. Furthermore, fatigue
and dyspnoea in COPD, whilst related, appear to be sep-
arate entities [11,4]. Using the FACIT-fatigue uni-dimen-
sional scale, no association between disease severity and
fatigue is noted [8]. However, the Multidimensional
Fatigue Inventory (MFI 20) [12], which is well validated in
COPD and shows moderate relationships with airflow
obstruction [10,13]. The MFI 20 provides a multi-dimen-
sional evaluation of fatigue, enabling investigation of the
different components. Since several factors are likely to be
involved in the development of COPD related fatigue
(COPD-RF), the use of a multi-dimensional tool enables
further elucidation of mechanistic pathways. For instance,
whilst hypoxia and hypoxaemia, impaired fat free mass
and loss of fatigue resistant muscle fibres are associated
with fatigue [14], it is not known if the variables relate to
physical or mental fatigue specifically. In healthy subjects,
acute exercise fatigue is associated with raised levels of
Interleukin 6 (IL6) [15,16]; possibly, this pathway is
important in the development of COPD-RF [17]. There
are few studies that comprehensively investigate predic-
tors of the different domains of fatigue in COPD. This
study attempts to draw together the psychological and
physiological aspects of fatigue to develop working mod-
els of COPD-RF, by using comparative data from healthy
age-matched subjects. This research hypothesises that
increases in each component of fatigue in COPD may be
predicted by differing factors. The aims of this study were
firstly, to provide comparative data of fatigue, using the
MFI 20, between COPD patients and healthy elderly sub-
jects and secondly, to explore possible predictors of
fatigue components of the MFI 20.
Methods
Full ethical consent was obtained for this cross sectional
study from the Royal Marsden Local Research Ethics Com-
mittee (London, UK). Patients and control subjects gave
written informed consent prior to entering the study.
Subject recruitment
A total of 80 COPD patients (defined as FEV1/FVC ratio <
0.7 with a general practitioner or chest physician diagno-
sis) and 37 healthy elderly subjects were recruited to the
study. Patients with stable COPD (no exacerbation or
change of medication in last 6 weeks) were recruited from
the chest clinic of St. George's Hospital. Figure 1 shows the
patient recruitment flow chart. Healthy subjects were
recruited from the staff and volunteers of St. George's Uni-
versity, St. George's Hospital and from an Open Univer-
sity group. Absence of airway obstruction was confirmed
by spirometry. Additionally, patients and subjects were
excluded if they had a history of significant inflammatory
co-morbidities such as carcinoma, rheumatoid arthritis or
stroke, unstable angina, a diagnosis of psychiatric disor-
ders, or mobility limiting conditions.
Assessments
Fifty nine patients included in the study attended the hos-
pital for a baseline morning assessment of approximately
2.5 - 3.5 hours (transport available). Assessment was car-
ried out over two days if necessary, for instance, when the
patient was too tired to continue. A further 15 house-
bound severe COPD patients were unable to attend the
hospital for assessment; for these patients an adapted
home assessment was provided.
Variables measured
Subjective fatigue
Fatigue was assessed in the morning prior to other assess-
ments in patients and healthy subjects using MFI 20, a 20-
item self-report validated instrument [12,18]. This tool
has been previously used in COPD population and it is
recommended as an outcome measure in clinical settings
[19]. The questionnaire asks subjects to describe how they
have been feeling lately. For issues of clarity this was spec-
ified as "within the last two weeks". The tool consists of
five dimensions covering General Fatigue (GF), Physical
Fatigue (PF), Reduced Activity (RA), Reduced Motivation
(RM) and Mental Fatigue (MF). Each dimension has 4
items, each item scored from 1-5 with higher scores repre-
senting greater levels of fatigue.
Depression and breathlessness scores
All participants completed the Hospital Anxiety and
Depression Scale (HADS). The HADS is a questionnaire
designed to measure depressive moods and anxiety sepa-
rately [20]. A score of 11 or higher indicates probable
presence of the mood disorder, but it is not a synonymous
of the diagnosis.
Baseline breathlessness level was assessed using the Med-
ical Research Council Dyspnoea Grade (MRC) [21].
Health Related QoL was measured using Saint George's
Respiratory Questionnaire (SGRQ) [22].
Physiological measures
For all participants height (cm) and weight (kg) were
measured. Body Mass (BMI) and Fat Free Mass (FFMI)
indices were determined from body composition meas-
urements using a non-invasive bioelectrical impedance
technique (Body composition analyser, Tanita Ltd BC-
418MA, UK). Baseline FEV1 and FVC were assessed using
a spirometer Micro Plus MS03 (Micro Medical Ltd,
Rochester UK) and according to BTS recommendations
[23]. GOLD classification was used to determine patients'
airway obstruction severity [24].Page 2 of 11
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Flow chart of recruitment and assessmentigure 1
Flow chart of recruitment and assessment.
Agreed: 
98 patients  
(81 hospital assessment and 
17 home assessment) & 
37 healthy subjects 
18 did not attend the first assessment 
6 patients and 2 healthy subjects excluded after 
an initial interview 
Assessed: 
74 patients 
(59 hospital assessment 
and 15 home assessment) & 
35 healthy subjects 
99 patients refused 
18 patients not contacted (17 change in address 
or telephone number, 1 RIP) 
15 patients excluded
Invited: 
230 patients & 
37 healthy subjects
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For all participants quadriceps maximal torque was meas-
ured using a "Cybex Norm™ Testing and Rehabilitation
System". The protocol consisted of 1 minute of consecu-
tive concentric knee extensions and flexions, performed
maximally at an angular velocity of 60°/sec, following a
10-repetition trial. The break between the trial and actual
test was 20 seconds. Maximum torque was recorded as the
best attempt during 1 minute isokinetic work of the dom-
inant side (FtLbs) and as FtLbs/subject bodyweight (lb)
*100.
Exercise tolerance
For patients only, maximal exercise tolerance was assessed
using the Incremental Shuttle Walking Test (ISWT), an
incremental, externally paced exercise capacity test con-
ducted according to standardised procedure [25]. Endur-
ance exercise tolerance was then assessed using the
Endurance Shuttle Walking Test (ESWT) [26]. Prior to and
after each test percutaneous arterial oxygen saturation
(SpO2) and heart rate were measured using a pulse oxym-
eter (Pulsox-3i-Konika Minolta, Singapore) applied to the
finger. Borg CR 10 (Dyspnoea assessment) and Borg Rat-
ing of Perceived Exertion (RPE) scales were scored after
each test [27,28].
Blood sampling
For patients only, a fasting, resting venous blood sample
was obtained from the median cubital vein and Inter-
leukin-6 (IL-6) was measured from serum. Blood samples
were centrifuged within 2 hours of collection and serum
was stored at -20°C until assay. The analysis was per-
formed on an Immulite® 1000 automated analyser (Sie-
mens Medical Solutions Diagnostics, formally Euro/DPC
Ltd Gwynedd Wales, UK). The limit of detection for serum
IL-6 was 0.2 pg/mL-1. Patients' haemoglobin (Hb) levels
were determined from their ear lobe capillary blood sam-
ple, using blood gas/electrolyte analyser (model 5700;
Instrumentation Laboratory, Lexington MA). Anaemia
was defined according to WHO criteria [29].
Home assessment
The 15 home assessments were as described above with
the exception of measures of exercise tolerance, muscle
strength and blood sampling.
Statistical analysis
Summary statistics of the healthy subjects' and COPD
patients' characteristics were reported. Independent sam-
ple t-tests or Mann-Whitney tests as appropriate were used
to test for differences between the patients and the healthy
subjects. The Kruskal-Wallis test was used to determine
differences between fatigue dimensions according to the
MRC score and GOLD classification with the significance
level set at α = 0.05. When significant differences were
found, post hoc analysis was carried out using Mann-
Whitney tests with Bonferroni correction. The data used to
measure fatigue are not metric and therefore multiple lin-
ear regression techniques are inappropriate. Due to the
small number of subjects, logistic rather than ordinal
regression was chosen to identify predictors of the 5
dimensions of fatigue; a backward elimination method
was used. Therefore for each dimension of fatigue, a
binominal category was defined using a cut-off point of
the highest value of fatigue in the healthy subjects. Values
above this point were considered as fatigued and values
below as not fatigued. Explanatory variables that were
independent of one another, according to appropriate
correlation tests were included in the initial regression
models. Other, clinically relevant variables, as identified
from literature [9,10,13,14,17,30,31] were also included.
The final models, presented here, are those where all the
remaining independent variables are statistically signifi-
cant predictors of the fatigue dimension under considera-
tion and which have the highest R2 value. The data from
15 home assessments were excluded due to the modified
assessment. All analyses were performed using SPSS 15.
Results
Comparative data: Fatigue in COPD subjects versus 
healthy older subjects
Seventy four mild-to-severe COPD patients and 35
healthy subjects completed all assessments.
There were no significant differences in fatigue according
to gender in either the COPD (52 male vs. 22 female) or
the healthy group (12 male vs. 23 female). Median scores
for COPD patients were significantly higher than those of
the healthy subjects in all dimensions of MFI 20. Table 1
shows the scores for fatigue and other variables and differ-
ences between COPD patients and the healthy subjects.
Fatigue and disease severity
Statistically significant differences in fatigue when catego-
rised according to the GOLD and MRC dyspnoea classifi-
cations were evident for selected dimensions of MFI 20
only (see figure 2 and figure 3).
Meaningful variables for fatigue dimensions
Regression analysis was performed on full data available
from 59 patients (40 male) aged 68.7 (8.1), mean (SD) %
predicted FEV1 48.2 (20.9) and FEV1/FVC ratio 0.45
(0.13). Clinically relevant variables were identified based
on literature and results of correlations with fatigue
dimensions. Following the initial regression analyses nine
possible predictors were identified: % predicted FEV1,
depression, muscle torque, ISWT, end exercise SpO2, IL6,
Borg RPE, BMI, age. The final decision on which variables
to include was determined by clinical relevance and by the
best possible model of predictive variables.Page 4 of 11
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The mean (SD) haemoglobin level was 15.6 (2.9) g/dL in
male and 14.6 (1.6) g/dL in female patients. Only 2
patients had values below normal. Anaemia was therefore
not a feature of the patient population and thus was not
included in the regression analysis. There were high corre-
lations between anxiety and depression, BMI and FFMI,
ISWT and ESWT. Hence anxiety, FFMI and ESWT were not
entered into the regression as independent variables as the
others were considered more important clinically.
MRC score as a measure of dyspnoea was initially consid-
ered as a predictor of fatigue. Although expected from lit-
erature and from the results presented in figure 3, it was
not a significant predictor for any of fatigue dimension
and it was eventually excluded in the final regression proc-
ess. Measures of quality of life (SGRQ) were collected to
enable baseline characterisation of the patients. Although
quality of life has been shown to be associated with
fatigue in previous studies [8,9], direction of causality is
unknown. It was felt that fatigue was more likely to be a
Table 1: Characteristics and comparison of COPD and healthy subject groups
COPD (n = 74) Healthy (n = 35) p value
MFI 20 General Fatigue 13 (5) 8 (4) p < 0.001
MFI 20 Physical Fatigue 16 (5.25) 7 (5) p < 0.001
MFI 20 Reduced Activity 13.5 (6) 6 (5) p < 0.001
MFI 20 Reduced Motivation 10 (6) 6 (4) p < 0.001
MFI 20 Mental Fatigue 8 (7) 6 (4) p = 0.008
% FEV1 46.5(20.0) 96.5(13.2) p < 0.001
FEV1/FVC ratio 0.44 (0.13) 0.78(0.1) p < 0.001
Age (yrs) 69.9 (8.4) 67.11 (8.8) NS
BMI (kg/m2) 26.2 (5.4) 25.2 (3.4) NS
FFMI (kg/m2) 18.2 (2.6) 17.9 (2.2) NS
Depression (HADS) 6 (5) 1 (3) p < 0.001
Anxiety (HADS) 7 (6) 3 (4) p < 0.001
Peak Tq (% BW) 38.6 (12.0)* 51.6 (14.5) p < 0.001
ISWT (m) 343.3 (183.9) * - -
Post walk SpO2 (%) 90.0(5.9)* - -
Borg exertion (RPE) 13(2.0)* - -
IL 6 (pg/mL) (n = 57) 5.4(5.9) * - -
MRC dyspnoea score 3 (2) - -
SGRQ 56.0 (27.4) - -
Data presented as median (IQR) for MFI 20-Multidimensional Fatigue Inventory, HADS - Hospital Anxiety and Depression scale, SGRQ - Saint 
George's Respiratory Questionnaire, total score, Borg exertion, MRC score or mean (SD) for % FEV1 - % predicted forced expiratory volume in 
one second, FEV1/FVC - Forced Expiratory Volume in one second/Forced Vital Capacity, BMI - Body Mass Index; FFMI - Fat Free Mass Index; Peak 
Tq (% BW) - quadriceps peak torque (% Body Weight), ISWT - Incremental Shuttle walk test, SpO2 - Percutaneous arterial oxygen saturation. *not 
measured in home-assessed patients (n = 59).Page 5 of 11
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tion, thus SGRQ data were not included in the regression
as independent predictors.
Predictors of fatigue in COPD
For GF the following 5 variables were entered: depression,
muscle torque, % predicted FEV1, end SpO2, IL 6; for PF:
depression, ISWT, % predicted FEV1 and age; for RA:
depression, ISWT, % predicted FEV1 and BMI; for RM:
depression, end Borg RPE and end SpO2 and for MF:
depression, IL6 and end SpO2. Table 2, 3, 4, 5 and 6 give
the results of the logistic regression analyses. Table 2
shows, for instance, that the significant predictors of GF
(as measured by Wald statistic) are depression, muscle
torque and end exercise SpO2. For every increase of 1 in
the depression score a patient is approximately 1.5 times
more likely to be fatigued and for lower end exercise SpO2
there is a slightly higher chance of being fatigued; simi-
larly lower muscle strength is associated with higher risk
of fatigue.
Summary
Fatigue score was significantly higher in COPD compare
to control group for all dimensions of MFI 20. After strat-
ification for MRC and GOLD classifications there were sig-
nificant differences only for selected dimensions of
fatigue. Fatigue, when considered as a multi-component
construct was explained by a different combination of var-
iables.
Discussion
The results from this study show that subjective fatigue
measured with MFI 20 was significantly higher in the
COPD group than in healthy elderly people. Previous
work supports these findings [8,32], which suggests that
the increased fatigue reflects disease entity and may there-
Box plots showing MFI 20 dimensions (median and IQR) in COPD patients for GOLD stagesFigure 2
Box plots showing MFI 20 dimensions (median and IQR) in COPD patients for GOLD stages. GOLD stage I & II (n 
= 27), III (n = 32) and IV (n = 15). Kruskal Wallis tests: p = 0.008 for Physical Fatigue and p = 0.045 for Reduced Activity; p > 
0.05 for General Fatigue, Reduced Motivation and Mental Fatigue; †Mann-Whitney test (Bonferroni correction p = 0.02).
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addressed in clinical practice. In contrast to other authors
[8] differences were found in fatigue according to GOLD
staging, however these differences were specific for
selected dimensions of fatigue only. The difference in
findings likely reflects the different fatigue tools used,
with this study using a multi-dimensional tool compared
with the FACIT-fatigue, a uni-dimensional tool.
Box plots showing MFI 20 dimensions (median and IQR) in COPD patients for MRC scoresFigure 3
Box plots showing MFI 20 dimensions (median and IQR) in COPD patients for MRC scores. MRC score 1&2 (n = 
31), 3 (n = 12), 4 (n = 17), 5 (n = 14). Kruskal Wallis tests: p = 0.001 for General Fatigue, p = 0.004 for Physical Fatigue, p = 
0.001 for Reduced Activity, p > .05 for Reduced Motivation and Mental Fatigue; †Mann-Whitney test (Bonferroni correction p 
= 0.008).
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Table 2: Logistic regression results for General Fatigue
MFI 20 Variables included Wald χ2 B (SE) Odd ratio
Exp b
95% CI lower-upper
General Fatigue
(n = 48)
HADS depression 8.1 0.43 (0.15) 1.54 1.14-2.07
Tq %BW 5.0 -0.13 (0.06) 0.88 0.79-0.98
End SpO2 2.9 -0.014 (0.08) 0.87 0.74-1.02
Constant 3.4 13.9 (7.6) 1109057
R2 = .62 (Nagelkerke); HADS depression-depression score of hospital anxiety and depression scale, Tq%BM - quadriceps muscle torque % of body 
mass, End SpO2 - percutaneous arterial saturation post walking testPage 7 of 11
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fatigue dimensions can be explained by different physio-
logical and psychological variables associated with COPD
and only depression was a common predictor. Although
according to MRC dyspnoea classification there were sig-
nificant differences for Reduced Activities, General and
Physical Fatigue, the regression analysis excluded dysp-
noea score as a possible predictive variable of fatigue.
Importantly, the cohort used in regression study differ
from one used in MRC classification analysis and data
from home-assessed most severe patients may have been
more insightful. Previous studies also showed associa-
tions between dyspnoea and fatigue [8,30,31]. Nonethe-
less, fatigue and dyspnoea are both subjective symptoms
of COPD and some of the patho-mechanisms of fatigue
may be common for those of dyspnoea. Therefore, this
may explain the close association between these symp-
toms. Since fatigue is not routinely assessed in current
clinical practice, the models from this study may help to
identify patients who are at risk of being fatigued and
develop effective fatigue management strategies. Further-
more, the regression analyses revealed that each compo-
nent could be explained by different variations. Hence,
the multi-rather than uni-dimensional assessment should
be considered. Over half of the variation in general fatigue
was explained by a combination of depression, exercise
de-saturation and muscle strength. These data then pro-
vide further support for the role of muscle training,
depression management and use of supplementary oxy-
gen in COPD. In this present study exercise de-saturation
was also a significant predictor for the MFI 20 Reduced
Motivation component. For Reduced Motivation; depres-
sion, post exercise saturation and exertion explained a lit-
tle less than 40% of the variation. This component
includes items such as 'I dread having to do things' and 'I
don't feel like doing anything'. Low oxygen levels may be
associated with changes in cognitive function [33,34] and
stimulate affective areas of the brain, mainly in the frontal
lobe, which is associated with motivational process
[35,36]. Feasibly, the administration of oxygen during
exertion may be associated with lower fatigue levels and
enhanced motivation. To date this application of oxygen
has not been explored.
For physical fatigue the best model, a combination of
depression, lung function and exercise tolerance,
Table 3: Logistic regression results for Physical Fatigue
MFI 20 Variables included Wald χ2 B (SE) Odd ratio
Exp b
95% CI lower-upper
Physical Fatigue
(n = 57)
HADS depression 11.3 0.47 (0.14) 1.61 1.22-2.12
%pred. FEV1 9.9 -0.11 (0.04) 0.90 0.83-0.96
ISWT 5.2 0.01 (0.003) 1.01 1.0-1.01
Age 2.8 0.9 (0.06) 1.1 0.98-1.22
Constant 2.6 -7.16 (4.48) 0.001
R2 = .57 (Nagelkerke). HADS depression-depression score of hospital anxiety and depression scale, %pred. FEV1 - % predicted forced expiratory 
volume in one second, ISWT-Incremental Shuttle Walk Test
Table 4: Logistic regression results for Reduced Activity
MFI 20 Variables included Wald χ2 B (SE) Odd ratio
Exp b
95% CI lower-upper
Reduced Activity
(n = 57)
%pred. FEV1 7.5 -0.06 (0.02) 0.95 0.91-0.98
BMI 4.5 0.19(0.08) 1.21 1.03-1.41
HADS depression 3.9 0.19 (0.94) 1.20 1.0-1.45
Constant 2.0 -3.12 (1.95) 0.04
R2 = .36 (Nagelkerke). %pred. FEV1 - % predicted forced expiratory volume in one second, BMI - Body Mass Index, HADS depression-depression 
score of hospital anxiety and depression scalePage 8 of 11
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nation as to how therapies that improve exercise tolerance
and depression can have an impact on fatigue in COPD
[37]. Muscle strength and exercise tolerance were signifi-
cant predictors for general and physical fatigue, respec-
tively. These two variables were highly correlated and
therefore only one was used in the regression analysis.
Muscle weakness and reduced exercise tolerance are well
recognised in the COPD population [38,39] and may be
important factors influencing COPD RF.
Around 40% of the variation in Reduced Activity was
explained by the combination of lung function, BMI and
depression. In this instance a higher BMI was associated
with greater fatigue. This probably reflects the U-shaped
curve nature of the association between BMI and out-
comes, both low and high BMI is generally associated
with poorer outcome [40]. Nutritional status remains an
important therapeutic outcome in the management of
COPD. Furthermore, in physically related dimensions of
fatigue the severity of airway obstruction explained a sig-
nificant amount of the variance, suggesting that treat-
ments which affect airflow obstruction may also benefit
the perception of physical fatigue. For mental fatigue few
COPD patients were identified as fatigued and the results
for this component should be treated with caution.
Anaemia may be one of the causes of fatigue and can be
present in COPD patients [41]; however, haemoglobin
levels were generally within the normal range in the
cohort, thus this factor could not be included in this anal-
ysis. Nevertheless, it is clear from this study, that COPD
RF remains a significant problem even in patients with
moderate disease and no anaemia. Although some varia-
bles were not included in the final regression model, they
may still play a role in the development of COPD RF. For
example, there was a strong correlation between anxiety
and depression, but it was decided only to include depres-
sion. Similarly, ESWT was strongly related to ISWT but
only the maximal test was included. Although IL6 was
considered a possible predictor, none of the final regres-
sion models included it, which may be due to its correla-
tion with both muscle strength and walking distance [42]
or reflects the need for other measures such as receptors.
Previous studies using a multiple regression identified
depression as a predictive variable of uni-dimansional
fatigue in COPD [8,30]. However, findings here reveal
that depression is a predictor for all dimensions of fatigue.
Conclusion
This study shows that all dimensions of fatigue are greater
in COPD than in healthy people of a similar age range.
Increased fatigue in this population is therefore a feature
Table 5: Logistic regression results for Reduced Motivation
MFI 20 Variables included Wald χ2 B (SE) Odd ratio
Exp b
95% CI lower-upper
Reduced Motivation
(n = 56)
Borg exertion 5.8 0.54 (0.22) 1.71 1.11-2.66
HADS depression 5.7 0.24 (0.10) 1.28 1.04-1.56
End SpO2 4.9 -0.13(0.06) 0.88 0.78-0.99
Constant 0.3 2.69 (5.28) 14.67
R2 = .37 (Nagelkerke). Borg exertion (score) post walk test, HADS depression-depression score of hospital anxiety and depression scale, End SpO2 
- percutaneous arterial saturation post walking test.
Table 6: Logistic regression results for Mental Fatigue
MFI 20 Variables included Wald χ2 B (SE) Odd ratio
Exp b
95% CI lower-upper
Mental Fatigue
(n = 52)
HADS depression 7.3 0.4 (0.15) 1.49 1.12-2.0
End SpO2 3.1 0.2 (0.12) 1.23 0.98-1.54
Constant 4.3 -23.06(11.16) 0.0
R2 = .38 (Nagelkerke). HADS depression-depression score of hospital anxiety and depression scale, End SpO2 - percutaneous arterial saturation 
post walking test.Page 9 of 11
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ponent construct and as such different aspects of fatigue
are influenced by different clinical manifestations. Com-
prehensive treatment of COPD-RF includes management
of depression, muscle weakness, optimisation of BMI and
exercise de-saturation levels. In contrast to other authors
it was found that fatigue differs according to GOLD stag-
ing, however this is relevant only for Physical Fatigue and
Reduced Activity. This study goes some way towards
explaining the mechanistic pathway of COPD-RF and pro-
vides information to target hitherto neglected treatments.
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